227 related articles for article (PubMed ID: 15199290)
1. Lanthanum carbonate: a new phosphate binder.
Behets GJ; Verberckmoes SC; D'Haese PC; De Broe ME
Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):403-9. PubMed ID: 15199290
[TBL] [Abstract][Full Text] [Related]
2. Lanthanum carbonate.
Freemont AJ
Drugs Today (Barc); 2006 Dec; 42(12):759-70. PubMed ID: 17285149
[TBL] [Abstract][Full Text] [Related]
3. Improving phosphate-binder therapy as a way forward.
Hutchison AJ
Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemia and phosphate binders.
Schucker JJ; Ward KE
Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
[TBL] [Abstract][Full Text] [Related]
5. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
[TBL] [Abstract][Full Text] [Related]
6. Lanthanum carbonate as a first-line phosphate binder: the "cons".
Drüeke TB
Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
[TBL] [Abstract][Full Text] [Related]
7. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
[TBL] [Abstract][Full Text] [Related]
8. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Albaaj F; Hutchison AJ
Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
[TBL] [Abstract][Full Text] [Related]
9. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Finn WF; Joy MS;
Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
[TBL] [Abstract][Full Text] [Related]
10. Phosphorus management in end-stage renal disease.
Finn WF
Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic use of the phosphate binder lanthanum carbonate.
Barton Pai A; Conner TA; McQuade CR
Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of the phosphate binder, lanthanum carbonate.
Damment SJ
Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
[TBL] [Abstract][Full Text] [Related]
13. Lanthanum carbonate--a first line phosphate binder?
de Freitas D; Donne RL; Hutchison AJ
Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
[TBL] [Abstract][Full Text] [Related]
14. Improving outcomes in hyperphosphataemia.
De Broe ME; D'Haese PC;
Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for hyperphosphatemia.
Bellinghieri G; Santoro D; Savica V
Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
[TBL] [Abstract][Full Text] [Related]
16. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
Altmann P; Barnett ME; Finn WF;
Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
[TBL] [Abstract][Full Text] [Related]
17. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
Damment SJ; Pennick M
Clin Pharmacokinet; 2008; 47(9):553-63. PubMed ID: 18698878
[TBL] [Abstract][Full Text] [Related]
19. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Albaaj F; Hutchison AJ
Expert Opin Pharmacother; 2005 Feb; 6(2):319-28. PubMed ID: 15757427
[TBL] [Abstract][Full Text] [Related]
20. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Cozzolino M; Brancaccio D
Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
